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Research digest: new horizons in heart failure therapy 
 
When the concept of tackling type 2 diabetes with a drug that enhances urinary excretion of glucose 
was first mooted, many felt the idea was speculative; for years, doctors had been trying to lessen 
urinary glucose loss, not accentuate it. Undeterred, several companies pressed on with their 
development of sodium-glucose co-transporter-2 (SGLT2) inhibitors. 
Fast forward to the present day and major trials have now shown unequivocally that, when given to 
patients with type 2 diabetes, this drug class lessens the chances of cardiovascular events and heart 
failure in patients with cardiovascular disease and, remarkably, also slows renal decline. The 
emergence of a diabetes drug with haemodynamic effects has resulted in closer interactions between 
diabetology and cardiology. The recent publication of the DAPA-HF trial—coinciding with its 
presentation at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in 
Barcelona, Spain in September—will make cardiologists take further notice of this drug class. 
DAPA-HF was a phase 3 trial in which 4744 patients with class II–IV reduced ejection fraction heart 
failure (HFrEF; 42% with diabetes) were randomly assigned to dapagliflozin 10 mg or matching placebo 
once daily. Both groups were well treated with drugs known to improve outcomes in HFrEF. After 18 
months, dapagliflozin recipients had a 26% (95% CI 15–35, p<0·001) reduced risk of the primary 
outcome of worsening heart failure or cardiovascular death, as well as an impressive 17% (3–29) 
reduced risk of death from any cause. Previous studies have shown that SGLT2 inhibition in people 
without type 2 diabetes leads to urinary glucose excretion and reductions in blood pressure and 
bodyweight, but these changes are modest compared with effects in those with type 2 diabetes. 
Therefore, perhaps the most notable finding in DAPA-HF was that the primary outcome benefit was 
near identical in participants with and without type 2 diabetes. This finding should widen the trialling 
of these drugs—eg, to patients following a recent myocardial infarction who do not have diabetes. No 
new safety issues emerged in the trial, with no excesses of hypoglycaemia, fluid volume depletion, or 
renal dysfunction, and no cases of Fournier gangrene. The results were so impressive that when 
presented at the European Society of Cardiology (ESC) Congress in Paris, France in August, the 
audience spontaneously applauded, recognising arguably the biggest advance in the treatment of 
HFrEF since angiotensin-converting-enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). 
An ideal heart failure drug would, in addition to lowering risk of adverse outcomes, improve symptoms 
and functional capacity. The DEFINE-HF trial—also presented at the EASD Annual Meeting—tested 
this possibility for SGLT2 inhibition in 263 patients with HFrEF, randomly assigning participants to the 
same treatment regimens as in DAPA-HF for 12 weeks. Dapagliflozin-treated patients had an 80% (95% 
CI 3–206%) greater chance of either a five-point improvement in the Kansas City Cardiomyopathy 
Questionnaire (KCCQ) overall summary score or a reduction of at least 20% in N-terminal pro-B-type 
natriuretic peptide (dual primary outcome). Improvements in many KCCQ subdomains were also 
noted and, as in DAPA-HF, benefits were similar in patients with or without type 2 diabetes. 
If the link between type 2 diabetes and HFrEF is strong, its link with preserved ejection fraction heart 
failure (HFpEF) is even stronger. HFpEF is now the most common form of heart failure, mortality rates 
remain high, and almost half of affected individuals have type 2 diabetes. Patients with type 2 diabetes 
and HFpEF have thicker left ventricles, higher B-type natriuretic peptide concentrations, more severe 
symptoms, and poorer outcomes than those with HFpEF but without diabetes. Unlike HFrEF, where 
incremental improvements in outcomes have been heralded in recent decades by landmark trials of 
several drugs, HFpEF has largely resisted any similar trend. Trials of ACE inhibitors, ARBs, and 
mineralocorticoid receptor antagonists have generally not shown clear benefit. 
In the PARAGON-HF trial—also presented at the ESC Congress—investigators assessed whether 
treatment of patients with HFpEF with sacubitril–valsartan would improve outcomes compared with 
use of valsartan alone. The trial follows on from the PARADIGM-HF trial, in which sacubitril–valsartan 
proved clinically superior to enalapril in patients with HFrEF. Of 4882 participants in PARAGON-HF, 43% 
had diabetes at baseline. The primary outcome was a composite of total hospital admissions for heart 
failure and cardiovascular deaths. Over the average follow-up of 35 months, 1903 events occurred in 
1083 participants, and those with diabetes again fared poorly, with a 60% higher event rate than in 
those without diabetes. Sacubitril–valsartan narrowly failed to show significant improvement in the 
primary outcome (rate ratio 0·87, 95% CI 0·75–1·01), but did improve heart failure symptoms and 
lower systolic blood pressure compared with valsartan alone. Even though the trial was negative in 
conventional statistical terms, it is notable that the comparator was not placebo but valsartan. It will 
be interesting to see how these mixed results are viewed in future guidelines. Whether SGLT2 
inhibition has a role in treating HFpEF is now an even bigger question: ongoing trials (EMPEROR-
Preserved [NCT03057951], DELIVER [NCT03619213]) should provide that answer in the next 2 years. 
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